<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152577</url>
  </required_header>
  <id_info>
    <org_study_id>ShangdongPH</org_study_id>
    <nct_id>NCT04152577</nct_id>
  </id_info>
  <brief_title>R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL</brief_title>
  <official_title>Lenalidomide, Rituximab and Combination Chemotherapy Versus Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Highly Aggressive Non-Hodgkin B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong Provincial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study，lenalidomide was added in the first-line treatment in the newly diagnosed
      highly invasively non-Hodgkin B-cell lymphoma. The R2-CHOP/R2-EPOCH etc was applied compared
      with the classical R-CHOP/R-EPOCH etc. The investigators tried to explore a more effective
      and safe treatment regimen for patients with high-risk B-cell lymphoma to improve the
      patient's poor prognosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lymphoma has become one of the top ten malignant tumors, of which non-Hodgkin's B-cell
      lymphoma accounts for the majority. As the classic first-line treatment, the emergence of the
      R-CHOP program has resulted in clinical cures for more than 1/2 of patients with B-cell
      lymphoma. But for patients with highly aggressively B cell lymphoma, most of them still
      suffer from disease recurrences due to R-CHOP treatment alone.

      In recent years, with the emergence of various new drugs, many researchers have tried to add
      new drugs to the classic R-CHOP program as a first-line treatment for non-Hodgkin B-cell
      lymphoma. As a new type of immunomodulator, lenalidomide was first approved for the treatment
      of multiple myeloma. In recent years, its role in refractory and relapsed B-cell lymphoma has
      gradually been recognized.

      In 2015, Nowakowski et al. published a clinical study of 64 patients with diffuse large
      B-cell lymphoma who used R2-CHOP in first-line therapy. It was found that R2-CHOP does not
      improve R-CHOP in patients with GCB. The effective rate of treatment and the 2-year survival
      rate of patients, but for patients with non-GCB type DLBCL with poor prognosis, the addition
      of lenalidomide can greatly improve the remission rate of the disease and improve the poor
      prognosis of patients.

      So, the investigators initiate this study to evaluate the efficacy of R2-CHOP/R2-EPOCH etc in
      newly diagnosed highly invasively non-Hodgkin B-cell lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 5, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate after 3 cycles</measure>
    <time_frame>at the end of 3 cycles( each cycle is 21 days)</time_frame>
    <description>Percentage of patients with complete remission （CR）or partial remission （PR）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate after 6 cycles</measure>
    <time_frame>at the end of 6 cycles( each cycle is 21 days)</time_frame>
    <description>Percentage of patients with complete remission （CR）or partial remission （PR）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival（PFS）</measure>
    <time_frame>2 years</time_frame>
    <description>Time from enrollment to tumor progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival（OS）</measure>
    <time_frame>2 years</time_frame>
    <description>Time from enrollment to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lymphoma, B-Cell</condition>
  <arm_group>
    <arm_group_label>R2-combination chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>R2-CHOP/CHOPE/DA-EPOCH/HD MTX
R2-CHOP :
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
R2-DA-EPOCH:
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
R2-HD MTX:
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>R-combination chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>R-CHOP/CHOPE/DA-EPOCH/HD MTX
R-CHOP :
Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
R-DA-EPOCH:
Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
R-HD MTX:
Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R2-combination chemotherapy</intervention_name>
    <description>R2-CHOP/CHOPE/DA-EPOCH/HD MTX
R2-CHOP :
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
R2-DA-EPOCH:
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
R2-HD MTX:
lenalidomide 25mg/d po D1-10; Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
    <arm_group_label>R2-combination chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-combination chemotherapy</intervention_name>
    <description>R-CHOP/CHOPE/DA-EPOCH/HD MTX
R-CHOP :
Rituximab：375mg/m2，ivgtt，D0 Cyclophosphamide 750mg / m2 d1, doxorubicin 70mg / m2 or Doxorubicin liposome 30-40 mg / m2 d2, vincristine 1.4mg / m2 or vindesine 3mg / m2 d2, prednisone 100mg d1-5
R-DA-EPOCH:
Rituximab：375mg/m2，ivgtt，D0 Epirubicin 15mg／m２ ,d1-4; Etoposide 50mg／m２ ,d1-4; Vincristine 0.4mg/ ｍ２ ，d1-4; Cyclophosphamide 750mg/ ｍ２ , d５; Prednisone 60mg/m２/d, d1-5;
R-HD MTX:
Rituximab：375mg/m2，ivgtt，D0； MTX 3.5g／ｍ２,ｄ1</description>
    <arm_group_label>R-combination chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Newly diagnosed highly aggressively B-Cell Non-Hodgkin's lymphoma (NHL) confirmed by
             histopathology

          2. The patient has at least ≥1 measurable tumor lesion with a diameter &gt;1.5 cm;

          3. The patient has not undergone systemic chemotherapy or immunotherapy before;

          4. ECOG score ≤ 2 points;

          5. Liver and kidney function meets the following conditions: creatinine clearance rate ≥
             30ml / min, total bilirubin, AST and ALT ≤ 2.5 × ULN;

          6. No history of malignant tumors within 5 years, except for cured carcinomas in situ
             such as basal cell carcinoma of the skin, cervical cancer, breast cancer, prostate
             cancer, etc.;

          7. agree to take contraceptive measures during the trial period and within 3 months after
             the end of the trial;

          8. Patients volunteered to participate in the study and signed informed consent.

        Exclusion Criteria:

          1. Serious cardiovascular and other important organs and blood, endocrine system lesions,
             and other history of malignant tumors;

          2. Severe mental illness;

          3. Pregnant or lactating women and men or women who intend to conceive in the near
             future;

          4. The expected survival time is less than 6 months;

          5. HBV, HCV or HIV infection or seropositive;

          6. there are active infections;

          7. Allergies or allergies to rituximab;

          8. Compliance or poor follow-up;

          9. Other circumstances that the investigator believes are not suitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xin Wang, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shandong Provincial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xin Wang, MD,PhD</last_name>
    <phone>+86-531-68778331</phone>
    <email>xinw8331@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiao Lv, MD,PhD</last_name>
    <phone>+86-531-68778331</phone>
    <email>lvxiao8377@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Hematology, Provincial Hospital Affiliated to Shandong University</name>
      <address>
        <city>Jin'an</city>
        <state>Shandong</state>
        <zip>250012</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xin Wang, MD, PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>xinw8331@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Xiao Lv, MD,PHD</last_name>
      <phone>86-531-68778331</phone>
      <email>lvxiao8377@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 4, 2019</last_update_submitted>
  <last_update_submitted_qc>November 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong Provincial Hospital</investigator_affiliation>
    <investigator_full_name>Wang Xin</investigator_full_name>
    <investigator_title>Director of Hematology Department</investigator_title>
  </responsible_party>
  <keyword>Lenalidomide，rituximab，chemotherapy，highly aggressive B-NHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Aggression</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

